AXGN

SEC source: 0000805928-25-000020 · wk-form4_1740605118.xml · nonDerivative · entry 2

Kemp Jens · CIK 0002007485 · Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,686

F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units ("PSUs") on February 22, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F3 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold on February 25, 2025 in multiple transactions at prices ranging from $16.42 to $17.32 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-25-000019 · wk-form4_1740605048.xml · nonDerivative · entry 2

Began Marc A · CIK 0001821352 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,686

F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units ("PSUs") on February 22, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F3 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold on February 25, 2025 in multiple transactions at prices ranging from $16.42 to $17.47 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-25-000018 · wk-form4_1740604988.xml · nonDerivative · entry 2

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 184,502

F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units ("PSUs") on February 22, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F3 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold on February 25, 2025 in multiple transactions at prices ranging from $16.42 to $17.47 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-25-000039 · wk-form4a_1741218773.xml · nonDerivative · entry 2

Kemp Jens · CIK 0002007485 · Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,686

F3 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units ("PSUs") on February 22, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F4 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold on February 25, 2025 in multiple transactions at prices ranging from $16.42 to $17.32 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · balance_after: The original Form 4, filed on February 26, 2025, failed to include 30,000 shares of common stock representing 30,000 restricted stock units in the beneficial number of shares of common stock outstanding in item 5 of Table I.

SEC source: 0000805928-25-000020 · wk-form4_1740605118.xml · nonDerivative · entry 1

Kemp Jens · CIK 0002007485 · Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria.

SEC source: 0000805928-25-000019 · wk-form4_1740605048.xml · nonDerivative · entry 1

Began Marc A · CIK 0001821352 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,500

F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria.

SEC source: 0000805928-25-000018 · wk-form4_1740604988.xml · nonDerivative · entry 1

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 185,474

F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria.

SEC source: 0000805928-25-000039 · wk-form4a_1741218773.xml · nonDerivative · entry 1

Kemp Jens · CIK 0002007485 · Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria.

F2 · balance_after: The original Form 4, filed on February 26, 2025, failed to include 30,000 shares of common stock representing 30,000 restricted stock units in the beneficial number of shares of common stock outstanding in item 5 of Table I.

SEC source: 0000805928-25-000002 · wk-form4_1736206734.xml · nonDerivative · entry 1

Naor Nir · CIK 0001982278 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 260,868

F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.

F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold on January 6, 2025 in multiple transactions at prices ranging from $14.37 to $15.26 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-24-000131 · wk-form4_1726604047.xml · nonDerivative · entry 1

THOMAS PAUL · CIK 0001166776 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,927

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock in connection with his appointment as Chairman of the Board of Directors.

SEC source: 0000805928-24-000129 · wk-form4_1726259429.xml · nonDerivative · entry 1

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 179,974

F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria.

SEC source: 0000805928-24-000121 · wk-form4_1725498802.xml · derivative · entry 2

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,904 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date.

SEC source: 0000805928-24-000121 · wk-form4_1725498802.xml · nonDerivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,016

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested on September 1, 2024.

SEC source: 0000805928-24-000120 · wk-form4_1725497999.xml · derivative · entry 2

NEELS GUIDO J · CIK 0001222362 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,904 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date.

SEC source: 0000805928-24-000120 · wk-form4_1725497999.xml · nonDerivative · entry 1

NEELS GUIDO J · CIK 0001222362 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,816

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested on September 1, 2024.

SEC source: 0000805928-24-000119 · wk-form4_1725497924.xml · derivative · entry 2

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,904 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date.

SEC source: 0000805928-24-000119 · wk-form4_1725497924.xml · nonDerivative · entry 1

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,816

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested on September 1, 2024.

SEC source: 0000805928-24-000118 · wk-form4_1725496885.xml · derivative · entry 2

Burke William P. Mr. · CIK 0001682069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,904 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date.

SEC source: 0000805928-24-000118 · wk-form4_1725496885.xml · nonDerivative · entry 1

Burke William P. Mr. · CIK 0001682069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,557

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested on September 1, 2024.

SEC source: 0000805928-24-000117 · wk-form4_1725494029.xml · derivative · entry 2

THOMAS PAUL · CIK 0001166776 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,904 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date.

SEC source: 0000805928-24-000117 · wk-form4_1725494029.xml · nonDerivative · entry 1

THOMAS PAUL · CIK 0001166776 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,052

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested on September 1, 2024.

SEC source: 0000805928-24-000116 · wk-form4_1725488740.xml · derivative · entry 2

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,904 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date.

SEC source: 0000805928-24-000116 · wk-form4_1725488740.xml · nonDerivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,557

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested on September 1, 2024.

SEC source: 0000805928-24-000114 · wk-form4_1725482772.xml · derivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,904 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date.

SEC source: 0000805928-24-000114 · wk-form4_1725482772.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,899

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested on September 1, 2024.

SEC source: 0000950170-24-094782 · ownership.xml · derivative · entry 1

DALE MICHAEL D · CIK 0001172346 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 450,000

Underlying: Common Stock · 450,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three year performance period beginning February 22, 2024 and ending February 22, 2027. The number of PSUs indicated reflects the "target" number of PSUs granted to the reporting person. The number of PSUs earned could range from 0% to 200% of such target number. The PSUs were granted pursuant to an inducement award agreement outside of the Issuer's Amended and Restated 2019 Long-Term Incentive Plan as a material inducement to the reporting person's acceptance of employment with the Issuer in accordance with NASDAQ Listing Rule 5635(c)(4)

F1 · derivative.exercise_date: Each performance stock unit ("PSU") represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three year performance period beginning February 22, 2024 and ending February 22, 2027. The number of PSUs indicated reflects the "target" number of PSUs granted to the reporting person. The number of PSUs earned could range from 0% to 200% of such target number. The PSUs were granted pursuant to an inducement award agreement outside of the Issuer's Amended and Restated 2019 Long-Term Incentive Plan as a material inducement to the reporting person's acceptance of employment with the Issuer in accordance with NASDAQ Listing Rule 5635(c)(4)

F1 · derivative.expiration_date: Each performance stock unit ("PSU") represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three year performance period beginning February 22, 2024 and ending February 22, 2027. The number of PSUs indicated reflects the "target" number of PSUs granted to the reporting person. The number of PSUs earned could range from 0% to 200% of such target number. The PSUs were granted pursuant to an inducement award agreement outside of the Issuer's Amended and Restated 2019 Long-Term Incentive Plan as a material inducement to the reporting person's acceptance of employment with the Issuer in accordance with NASDAQ Listing Rule 5635(c)(4)

SEC source: 0000805928-25-000004 · wk-form5_1736206828.xml · nonDerivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,082

F1 · date: Discloses an inadverent failure to report a purchase by the individual made in 2024.

SEC source: 0000805928-24-000103 · wk-form4_1718058239.xml · derivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,248

Underlying: Common Stock · 18,248 shares

Expires 2034-06-06

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 6, 2025, one year from the anniversary of the grant date. One-half of the annual equity grant is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-24-000103 · wk-form4_1718058239.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,995

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

SEC source: 0000805928-24-000101 · wk-form4_1718058141.xml · derivative · entry 2

Burke William P. Mr. · CIK 0001682069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,248

Underlying: Common Stock · 18,248 shares

Expires 2034-06-06

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 6, 2025, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-24-000101 · wk-form4_1718058141.xml · nonDerivative · entry 1

Burke William P. Mr. · CIK 0001682069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,653

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

SEC source: 0000805928-24-000099 · wk-form4_1718058050.xml · derivative · entry 2

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,248

Underlying: Common Stock · 18,248 shares

Expires 2034-06-06

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 6, 2025, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-24-000099 · wk-form4_1718058050.xml · nonDerivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,112

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

SEC source: 0000805928-24-000097 · wk-form4_1718057952.xml · derivative · entry 2

THOMAS PAUL · CIK 0001166776 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,248

Underlying: Common Stock · 18,248 shares

Expires 2034-06-06

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 6, 2025, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-24-000097 · wk-form4_1718057952.xml · nonDerivative · entry 1

THOMAS PAUL · CIK 0001166776 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,148

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

SEC source: 0000805928-24-000091 · wk-form4_1718057504.xml · derivative · entry 2

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,248

Underlying: Common Stock · 18,248 shares

Expires 2034-06-06

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 6, 2025, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-24-000091 · wk-form4_1718057504.xml · nonDerivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,653

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

SEC source: 0000805928-24-000095 · wk-form4_1718057710.xml · derivative · entry 2

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,248

Underlying: Common Stock · 18,248 shares

Expires 2034-06-06

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 6, 2025, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-24-000095 · wk-form4_1718057710.xml · nonDerivative · entry 1

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,912

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

SEC source: 0000805928-24-000093 · wk-form4_1718057618.xml · derivative · entry 2

NEELS GUIDO J · CIK 0001222362 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,248

Underlying: Common Stock · 18,248 shares

Expires 2034-06-06

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 6, 2025, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-24-000093 · wk-form4_1718057618.xml · nonDerivative · entry 1

NEELS GUIDO J · CIK 0001222362 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,912

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

SEC source: 0000805928-24-000089 · wk-form4_1718057423.xml · derivative · entry 2

Weiler Kathy Johnson · CIK 0001979466 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,248

Underlying: Common Stock · 18,248 shares

Expires 2034-06-06

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 6, 2025, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-24-000089 · wk-form4_1718057423.xml · nonDerivative · entry 1

Weiler Kathy Johnson · CIK 0001979466 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,653

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

SEC source: 0000805928-24-000075 · wk-form4_1717706957.xml · derivative · entry 2

Freitag Gregory Gene · CIK 0001492710 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,904 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F1 · derivative.exercise_date: Effective June 4, 2024, the Board of Directors accelerated the vesting of outstanding and unvested equity totaling 11, 904 shares of common stock.

F1 · derivative.expiration_date: Effective June 4, 2024, the Board of Directors accelerated the vesting of outstanding and unvested equity totaling 11, 904 shares of common stock.

SEC source: 0000805928-24-000075 · wk-form4_1717706957.xml · nonDerivative · entry 1

Freitag Gregory Gene · CIK 0001492710 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 283,498

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Effective June 4, 2024, the Board of Directors accelerated the vesting of outstanding and unvested equity totaling 11, 904 shares of common stock.

SEC source: 0000805928-24-000051 · wk-form4_1711417407.xml · nonDerivative · entry 6

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,143,788

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-24-000051 · wk-form4_1711417407.xml · nonDerivative · entry 4

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,133,979

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-24-000051 · wk-form4_1711417407.xml · nonDerivative · entry 2

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,124,565

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-24-000049 · wk-form4_1711417219.xml · nonDerivative · entry 6

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 177,474

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-24-000049 · wk-form4_1711417219.xml · nonDerivative · entry 4

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 167,890

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.